Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
19.4.2022 12:00:00 EEST | Business Wire | Press release
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Contact information
Claudio Hidalgo Cantabrana, PhD
claudio.hidalgo@microviable.com
(+34)670034435
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Enhances Support for AI Workloads at Massive Scale23.6.2026 17:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced the release of StorageGRID 12.1, designed to help customers scale AI and other modern workloads with a federated global namespace. The new capabilities improve how data is accessed, processed, and managed across distributed environments to support AI data pipelines, data lakes, and modern object-based applications. Organizations are contending with rapid growth in unstructured data to serve AI workloads while also managing that data across increasingly distributed hybrid environments. In its Object Storage Solutions Landscape, Q1 2026 report, Forrester notes that the rise of generative AI has pushed object storage further into an AI‑optimized data platform beyond its historical uses supporting enterprise data strategies with scalable, durable storage for unstructured data, media, and backups. The updates to NetApp StorageGRID enable organizations to leverage their object data for these emerging uses wi
Otonal Launches Localization Service to Adapt English Podcasts and Audio Ads for the Japanese Market23.6.2026 17:00:00 EEST | Press release
Otonal Inc., a Tokyo-based digital audio advertising and podcast technology company, has officially launched a specialized audio localization service designed to help global brands and media companies adapt their English-language podcasts and audio advertisements for the Japanese market. Audio Ad Localization https://otonal.co.jp/en/audioad-localization/ Podcast Localization https://otonal.co.jp/en/podcast-localization/ While many translation vendors focus on text-based, one-size-fits-all translation, Otonal’s service addresses the distinct challenges of audio-first localization. The service goes beyond standard translation by rebuilding scripts for spoken Japanese, ensuring precise 15- and 30-second ad timings, adapting the content to local cultural context, and casting native Japanese voice talent suited to the content and delivery environment to maintain brand authority and tone. Japan ranks among the world's leading economies and is one of Asia’s largest advertising markets, making
GigaDevice and Qt Group Announce Global Partnership to Advance the Embedded GUI Ecosystem23.6.2026 17:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially entered a strategic partnership with Qt Group, a global leader in software design, development, and quality assurance solutions. Leveraging the GD32H7 high-performance MCU series, the two companies will collaborate to optimize and enhance embedded GUI solutions, enabling developers to create more intuitive, visually rich, and responsive user experiences. This collaboration further expands GigaDevice’s ecosystem strategy in advanced human-machine interface (HMI) and establishes a solid foundation for future innovation across smart industry solutions, energy storage systems, smart home devices, and consumer electronics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623351273/en/ GigaDevice and Qt Group Announce Global Partnership to Advance the Embedded GUI Ecosystem As IoT,
Andersen Global Adds Andersen in Indonesia23.6.2026 16:30:00 EEST | Press release
Andersen Global strengthens its footprint in Southeast Asia as VDB Loi in Indonesia rebrands to Andersen in Indonesia, becoming the newest member firm to join the organization. Andersen in Indonesia provides tax and legal advisory services to multinational companies and foreign investors operating in the Indonesian market. The firm combines decades of market experience with a practical approach focused on delivering clear, tailored guidance across complex regulatory and cross-border matters. “Adopting the Andersen brand reflects our commitment to providing clients with high-quality, practical tax and legal advice supported by broader international collaboration,” said Tommy Hendharto Oetomo, managing partner of Andersen in Indonesia. “Clients operating in Indonesia require increasingly coordinated cross-border support. Becoming a member firm strengthens our ability to deliver that service with consistency and clarity.” “Indonesia remains an important market for organizations investing
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 16:30:00 EEST | Press release
Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Research and Development and Chief Medical Officer, Healthcare business of Merck. “By leveraging Saturnus' expertise and cutting-edge approach, we can build upon our armed antibodies capabilities and explore novel directions to rapidly bring new, targeted treatments to patients.” “The launch of Saturnus through a foundati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom